Background As previously shown, the sympathetic nervous system (SNS) shows proinfl ammatory activity during initiation of arthritis but is anti-infl ammatory in established collagen-induced arthritis (CIA). Interleukin 10 (IL-10)-producing B cells suppress arthritis and are a potential target of the SNS because (1) B cells express functional β 2 -adrenoceptors (β 2 ARs) and (2) IL-10, at least in monocytes/macrophages, is regulated in a cAMP/ PKA/CREB-dependent manner. Objective To test the hypothesis that anti-infl ammatory effects of the SNS in CIA are mediated by stimulating IL-10-producing anti-infl ammatory B cells. Methods Collagen-induced arthritis in DBA/1 mice, sympathectomy, adoptive B cell transfer, in vitro B cell culture, and assessment of B cell IL-10 production. Results and conclusion Mice treated with B cells from SNS-intact mice showed less severe arthritis than mice treated with B cells from sympathectomised mice. This anti-infl ammatory action of B cells from SNS-intact mice correlated with increased IL-10 produced by B cells, which was mediated by norepinephrine (NE), in a β 2 AR, PKA-dependent manner. However, an NE-mediated increase in IL-10 was seen only in B cells from immunised but not naive mice, explaining in part the antiinfl ammatory properties of the SNS in the late phase of arthritis. Finally, animals treated with B cells isolated from immunised mice and activated in vitro in the presence of a β 2 AR stimulus showed a decrease in arthritis severity in comparison with controls, an approach that might be used for future cellular treatment strategies.
INTRODUCTION
The depletion of CD20+ B cells as a treatment option for some rheumatic disorders-for example, rheumatoid arthritis, has raised again the proposition that B cells have a pathogenetic role in these disorders. However, depletion of all CD20+ cells is an unspecifi c approach and risks the occurrence of serious side effects such as infection. The optimal treatment for B cells would be specifi c depletion of autoreactive B cells, on the one hand, and promotion of anti-infl ammatory B cells, on the other. The mechanisms by which antiinfl ammatory B cells suppress chronic infl ammation in arthritis are not completely understood. However, one hallmark of anti-arthritic regulatory B cells is their ability to produce interleukin 10 (IL-10). 1 IL-10 is an anti-infl ammatory cytokine, which suppresses antigen presentation by antigen-presenting cells, downregulates major histocompatibility complex II molecules and inhibits the expression of co-stimulatory molecules, preventing suffi cient costimulation of antigen-specifi c T cells. Additionally, IL-10 directly suppresses the production of proinfl ammatory cytokines, chemokines and matrix metalloproteinases in macrophages (reviewed by Mosser and Zhang 2 ), which explains its anti-infl ammatory potential in arthritis. The overall effect of IL-10 on the whole B-cell population is stimulatory rather than immunosuppressive because IL-10 leads to prolonged survival, augments co-stimulation and induces class switch recombination. 2 Nevertheless, a subpopulation of IL-10-producing B cells, so called CD1d high CD5 high B10 cells, 3 clearly shows antiinfl ammatory properties in arthritis. 1 4 The human and murine promoter of the IL-10 gene contains several CREB-responsive elements. 5 6 Thus, it is not surprising that IL-10 production can be regulated through PKA/CREB-dependent mechanisms, which have been shown in THP-1 cells and macrophages. 5 7 Activity of PKA is increased by cAMP, which is generated, following the stimulation of Gs protein coupled receptors, such as the β 2 -adrenoceptor (β 2 AR); a functional β 2 AR has also been shown to be expressed on B cells. 8 9 Additionally, we reported in collagen type II-induced arthritis (CIA) that the sympathetic nervous system (SNS) with its main neurotransmitter norepinephrine (NE) has a role in regulating IL-10 in arthritis and has a profound effect on arthritis severity. 10 Furthermore, it has been shown that the SNS plays a proinfl ammatory role in the early phase and an anti-infl ammatory role in the late phase of the disease. 10 11 The proinfl ammatory effect of the SNS in the early phase of the disease can be mediated via increasing proinfl ammatory cytokines, such as interferon γ produced by T cells. 12 Additionally, it has been reported that FOXP3-negative CD4+CD25+ T cells also contribute to the proinfl ammatory effect of the SNS in the early phase of CIA. 11 However, the anti-infl ammatory action of the SNS in the late phase of CIA has not yet been elucidated.
In this study, we tested the hypothesis that anti-infl ammatory effects of the SNS in CIA are mediated by stimulating IL-10 producing antiinfl ammatory B cells. fed standard laboratory chow and water ad libitum. There was a 12 h light--dark cycle. Experiments were conducted according to institutional and governmental regulations for animal use (Government of the Oberpfalz AZ 54-2531.1-24/06).
Experimental arthritis was induced in DBA/1 mice, as previously described. 10 On day 0, mice were immunised intradermally at the base of the tail with 100 μg of bovine type II collagen (CII; Chondrex, Redmond, Washington, USA) emulsifi ed in an equal volume of complete Freund's adjuvant (CFA; Sigma-Aldrich Chemie, München, Germany). A booster immunisation (100 μg CII in CFA) was administered on day 21 as indicated. Clinical scoring points were assigned to each limb to assess arthritis as described previously. 13 A score of 0 (no swelling),1 (light swelling) or 2 (strong swelling) was determined for four toes at each paw, four paws and ankle/wrist joints. The maximum score for each mouse was 48 points. Arthritis scoring was performed in a blinded manner, by the same technical assistant, always at the same time of the day (11:00-12:00).
Adoptive transfer experiments
Three groups of mice were immunised as described above (control donor mice, sympathectomised donor mice and sympathectomised recipient mice, fi gure 1A). On day 28, donor mice were killed by cervical dislocation, spleens were removed and immediately put into ice-cold phosphate-buffered saline (PBS). Splenectomy was performed in recipient mice at day 28 to remove the majority of the intrinsic B-cell pool. After preparing single-cell suspensions of donor splenocytes, B cells were isolated by magnetic bead cell sorting using mouse anti-B220 magnetic beads (MACS MicroBeads; Miltenyi Biotec, Bergisch Gladbach, Germany). After isolation, >95% of the cells were CD19+/CD20+ B cells as assessed by fl uorescence activated cell sorter (FACS) analysis. Donor B cells (5×10 6 /200 μl PBS) were then injected into the tail vein of recipient mice (day 28 post-immunisation (p.i.)). One group received 200 μl PBS as treatment control (fi gure 1A). After transfer, clinical scores were obtained every 2-3 days until the end of experiment (day 63). After sacrifi cing the mice, heart blood was obtained and anti-CII antibody titres were determined in serum using a commercially available ELISA kit (MD Biosciences GmbH, Zürich, Switzerland).
Culture of splenocytes and B cells
Spleens were removed between 11:00 and 12:00. Single-cell suspensions were obtained by passing spleens through a nylon mesh. For splenocyte cultures, 5×10 5 cells/200 μl were cultured in complete RPMI medium (cRPMI: RPMI 1640, 25 mM HEPES, pH 7.4, 5% fetal calf serum, 30 μM mercaptoethanol, 0.57 mM ascorbic acid, 100 U/ml penicillin, 100 μg/ml streptomycin (all from Sigma, Munich, Germany)) in 96-well plates and stimulated with anti-CD40 (clone: FGK 45.5, Miltenyi Biotec, Bergisch Gladbach, Germany, 5 μg/ml) and bovine CII (Chondrex, Redmond, Washington, USA, 50 μg/ml) in the presence or absence of NE (10 -6 M, Sigma) for 4-5 days. For B-cell cultures, cells were isolated using magnetic bead cell sorting by depleting CD43-, CD4-and Ter119+ cells from whole splenocyte suspensions (B-cell isolation kit, Miltenyi Biotec, Germany). After isolation, >96% of the cells were CD19/CD20 positive B cells. Cells were resuspended in cRPMI containing anti-CD40 (5 μg/ml, clone: FGK 45.5, Milteyi Biotec, Bergisch Gladbach, Germany) and functional grade IL-4 (1 ng/ml, eBioscience, Frankfurt, Germany) and cultured at a density of 2×10 6 cells/ml in 24-well plates for 4-5 days in the presence or absence of NE, the β 2 AR specifi c agonist terbutaline, the protein kinase A (PKA) inhibitor H89, or the specifi c β 2 AR antagonist nadolol at indicated concentrations. For experiments using H89 or nadolol, cells were incubated for 30 min before adding NE or terbutaline, respectively.
Treatment of mice with early arthritis with cultured B cells
Splenic B cells were obtained from immunised mice at day 21 after immunisation and resuspended in cRPMI containing anti-CD40/IL-4 as described above. B cells were cultured for 5 days in 12-well plates at of 2×10 6 /ml in the presence or absence of NE, or terbutaline, or terbutaline + nadolol as indicated. After 5 days, cells were counted, washed fi ve times and resuspended in PBS at 2×10 6 live B cells/100 μl. Immunised mice beginning to show signs of synovitis at day 18 were treated with 2×10 6 B cells intravenously and the arthritis score was recorded thereafter.
Restimulation and assessment of IL-10 production
Restimulation of cultured cells and assessment of intracellular IL-10 was performed in accordance with methods published elsewhere. 1 3 Briefl y, after 4-5 days of culture cells were stimulated with phorbol myristate actetate (PMA; 50 ng/ml; Sigma), ionomycin (500 ng/ml; Sigma) and lipopolysaccharides (LPS, 10 μg/ml), as indicated. For IL-10 protein detection, cell-free supernatant was analysed using a BD OptEIA mouse IL-10 ELISA kit (BD Bioscience, Heidelberg, Germany). For intracellular FACS analysis, brefeldin A (10 μg/ml; Sigma) was added together with PMA and ionomycin. Cells were stained with fl uorescein isothiocyanate-anti-mouse CD19 (clone: MB 19-1, eBioscience) for 15 min on ice. Then cells were fi xed (2% paraformaldehyde, 20 min at 4°C), permeabilised using Cytofi x/ Cytoperm (BD-Pharmingen, Heidelberg, Germany) and stained with phycoerythrin-IL-10 monoclonal antibody (clone: JES5-16E3; eBioscience) or respective isotype control for 25 min on ice. FACS analysis was performed on a FACS Calibur (Becton Dickinson Immunocytometry Systems, San Jose, California, USA). Data were analysed with FlowJo Software (V.7.2.4.; Tree Star Inc, Ashland, Oregon, USA) or WinMDI2.8 (http://facs. scripps.edu/software.html), respectively.
Sympathectomy
Sympathectomy was performed using saporin-coupled antidopamine-β-hydroxylase antibodies or saporin-coupled control antibodies (Advanced Targeting Systems, San Diego, California, USA) 10 11 by intraperitoneal injection (5 μg per animal in PBS) 7 days before immunisation. The NE content in the spleen was reduced by 78% at the time of immunisation, demonstrating the effi cacy of sympathectomy.
Statistical analysis
The non-parametric Mann-Whitney test was used to compare two groups and analysis of variance with post hoc tests was used to compare multiple groups. All analyses were conducted using Sigma Plot for Windows (version 11; Systat software Inc.). p Values <0.05 were considered signifi cant.
RESULTS

The SNS ameliorates CIA by promoting anti-infl ammatory B cells in vivo
To test the hypothesis that the SNS promotes the development of anti-infl ammatory B cells in CIA, B cells were adoptively transferred as described above and as shown in fi gure1A. In arthritic mice treated with B cells from SNS-intact mice arthritis group.bmj.com on September 4, 2017 -Published by http://ard.bmj.com/ Downloaded from progression stopped about 14 days after treatment (fi gure1B), whereas treatment with B cells obtained from SNS-depleted animals resulted in a short-term aggravation of the disease as compared with the PBS-treated control group (fi gure 1B). This result supports the hypothesis that the SNS promotes development of B cells that show anti-infl ammatory properties in the CIA mouse model. The effect was not mediated by a change in anti-CII antibody titres at day 63. FACS analysis also showed that the percentage of B cells in the spleen and in peripheral blood was not infl uenced by sympathectomy (data not shown).
The SNS increases IL-10 produced by B cells in vivo
B cells producing IL-10 have an anti-infl ammatory action in CIA, and the regulatory regions of the IL-10 gene contain cAMPresponsive elements, 1 6 rendering IL-10-producing B cells a possible target for the SNS. To determine if the SNS changes the 2B) . When B cells were isolated from non-immunised animals sympathectomy did not infl uence the amount of IL-10 produced (data not shown). These result suggest that one function of the SNS in vivo is to promote IL-10-producing B cells during activation after immunisation with CII and CFA.
Norepinephrine differentially regulates IL-10 produced by B cells from naive or antigen-experienced spleens
Owing to earlier fi ndings that the SNS shows proinfl ammatory properties during the early phase and anti-infl ammatory properties during the late phases of CIA, 10 it was determined if NE, the main SNS neurotransmitter, differentially regulates IL-10 produced by cultured naïve splenocytes as compared with splenocytes obtained from antigen-experienced mice. Antigen-experienced splenocytes cultured for 4-5 days in the presence of anti-CD40, CII and NE showed increased IL-10 production after restimulation with PMA, ionomycin and LPS, as compared with cells in the absence of NE (fi gure 3A). FACS analysis showed that an increase in intracellular IL-10 in lymphocytes was mainly seen in CD19+ B cells (fi gure 3B). However, this NE-induced increase in IL-10 was not seen when naïve-splenocytes were used in a similar experiment (fi gure 3C), indicating that immunisation before stimulation with NE renders some IL-10-producing, antigen-experienced splenocytes-for example, B cells, responsive to this neurotransmitter.
Norepinephrine acts directly on B cells to increase IL-10 production
To determine whether the increase in IL-10-producing B cells, after activation of splenocytes in the presence of NE is dependent on cells other than B cells in the culture, we isolated B cells from naive and antigen-experienced spleens and activated them with anti-CD40 and IL-4 in the absence (Ctrl) or presence of NE for 5 days and analysed IL-10+/CD19+ cells by FACS (fi gure 4A). The results are expressed as a percentage of control (% Ctrl, anti-CD40/IL-4 only). The absolute values for the percentage of IL-10+/CD19+ B cells from naïve mice (3.1% × 1.2) and antigenexperienced mice (2.6% × 1.3) were not signifi cantly different (p=0.953). As shown in fi gure 4A, NE in a concentration-dependent manner increases IL-10+/CD19+ B cells when isolated from spleens of mice immunised with CII/CFA (day p.i. 35-65). The increase was signifi cant at concentrations of 10 -8 to 10 -6 mol/l (fi gure 4A, solid circles). However, when B cells from naive mice were used, the population of IL-10+ B cells did not change in the presence of NE (fi gure 4A, open circles). These results show that NE directly acts on B cells to increase IL-10+ cells, but only when the cells were taken from antigen-experienced spleens.
Norepinephrine increases IL-10 produced by B cells in a β2AR/PKA-dependent manner
Since it is known that B cells express functional β 2 AR, we next determined if specifi c stimulation of this receptor with terbutaline could mimic the effect of NE. Terbutaline increased IL-10 protein produced by B cells (isolated at day 35-40 p.i.) in a concentration-dependent manner (fi gure 4B). Additionally, the use of a specifi c PKA inhibitor, H89, showed that the terbutaline-induced increase in IL-10 was mediated through a PKAdependent pathway (fi gure 4C). The addition of H89 prevented the increase of IL-10, and also reversed the terbutaline effect, resulting in decreased IL-10 production. This result suggests a second signalling pathway downstream of the β 2 AR, which leads to a decrease in IL-10 production upon stimulation of the receptor. Taken together, these results suggest that the increase 
Treatment of CIA with β2AR-stimulated B cells isolated from antigen-experienced mice ameliorates disease progression
To show that the increase in IL-10+ B cells after β 2 AR stimulation of B cells from antigen-experienced mice in vitro is of relevance in vivo, arthritic mice were treated with B cells activated in the absence or presence of NE, terbutaline, or terbutaline + nadolol, respectively (fi gure 5A). Mice treated with anti-CD40/ IL-4-activated B cells (B-cell control) or PBS, respectively, showed the expected increase of arthritis severity over time (fi gure 5B). There was a trend towards a faster increase of arthritis scores in the B-cell control group as compared with PBS control in the fi rst 10 days after treatment (p = 0.074), but no overall signifi cant difference (p=0.099). On the other hand, mice receiving B cells activated in the presence of either terbutaline or NE showed signifi cantly reduced arthritis severity as compared with controls 
DISCUSSION
Recent studies using the CIA model system show, that the SNS has a dual role with respect to disease severity, with proinfl ammatory activity in the early phase and an anti-infl ammatory infl uence in the late phase of arthritis. 10 11 Our results in this study suggest that the anti-infl ammatory activity of the SNS in the late phase of arthritis is, at least in part, mediated by increasing the anti-infl ammatory properties of B cells. We propose that in the late phase of CIA a sympathetic stimulus increases the percentage of IL-10-producing, anti-infl ammatory B cells, which can slow down arthritis progression. 1 Our results do not exclude the possibility that the SNS also infl uences other cells-for example, monocytes/macrophages, which have been shown to increase IL-10 production after stimulation of β 2 AR in the human system. 5 7 14 However, transferring splenic B cells in vitro, activated in the presence of a β 2 AR stimulus, is suffi cient to signifi cantly slow arthritis progression, showing the important role of the SNS and B cells, respectively, in modulating disease severity in arthritis.
A necessary prerequisite for the SNS to increase IL-10-producing B cells was prior immunisation with CII and CFA, which underlines the importance of this mechanism after initiation of arthritis (late phase). The need for prior immunisation indicates that a proinfl ammatory milieu in the spleen is important to render naive B cells responsive for a β 2 AR-induced increase in IL-10. The reason for this is unclear. However, one possibility might be an increase in β 2 AR signalling capacity by decreasing G-protein-coupled receptor kinase (GRK)-2, which was reported to be decreased in peripheral blood mononuclear cells from patients with rheumatoid arthritis and upon antigen exposure in B and T cells in a rat model of adjuvant arthritis. 15 16 This leads to the hypothesis that an immune challenge decreases GRK-2 in naïve B cells, resulting in less β 2 AR phosphorylation, which slows internalisation and desensitisation of β 2 ARs. This results in increased and prolonged β 2 AR signalling, which might cross a certain threshold to initiate PKA-dependent IL-10 production in B cells.
The importance of IL-10 in modulating arthritis severity is underlined by several correlative studies showing a link between genetic variation at the IL-10 gene locus and severity of arthritis, 17 18 but human studies treating arthritis with systemic IL-10 showed almost no effect (reviewed by Asadullah et al 19 ). However, a small number of antigen-specifi c T cells transfected to produce IL-10 were capable of suppressing infl ammation in proteoglycan-induced arthritis, 20 probably by cell-cell interaction at the site of infl ammation without an increase in systemic IL-10. This fi ts together with our results, which show no change in IL-10 serum levels upon transfer of β 2 AR-stimulated B cells (data not shown). It was not in the scope of this study to delineate, whether local suppressive effects occur in the joints, the lymph nodes, or the spleen. However, in adoptive transfer experiments, recipient animals were splenectomised before transfer of B cells, which indicates that homing to the spleen is not necessary for the suppressive effect of B cells from SNS-intact animals.
As mentioned in the introduction, one problem with B-cell depleting strategies in rheumatic disease is the unselective approach, which depletes both, proinfl ammatory and antiinfl ammatory B cells. In light of our results, it might be possible to enrich anti-arthritic B cells in vitro using β 2 -adrenergic stimuli. Combining this approach with B-cell depletion and retransfer of in vitro generated anti-arthritic B cells might open new therapeutic possibilities for the future.
